DEVELOPMENTAL TYPE II PNEUMOCYTE PROTEIN PHOSPHORYLATION

$335,302R01FY2000HLNIH

Children'S Hospital Los Angeles, Los Angeles CA

Investigators

Linked publications & trials

Paper 28821490 Paper 26160872 Paper 23967234 Paper 22713487 Paper 22685326 Paper 22610556 Paper 22299047 Paper 21700959 Paper 21460122 Paper 21385765 Paper 21385574 Paper 21246661 Paper 21148187 Paper 21129374 Paper 20691848 Paper 20351039 Paper 20204620 Paper 20096867 Paper 19926868 Paper 19755154 Paper 19659647 Paper 19559694 Paper 19498056 Paper 19237431 Paper 19105622 Paper 18955379 Paper 18719226 Paper 18684721 Paper 18528385 Paper 18321928 Paper 18297731 Paper 18258849 Paper 18245268 Paper 18082381 Paper 17936056 Paper 17931953 Paper 17560563 Paper 16989802 Paper 16494859 Paper 16375885 Paper 15950607 Paper 15817505 Paper 15681399 Paper 15591413 Paper 15579626 Paper 14977631 Paper 14711801 Paper 14644509 Paper 14499647 Paper 12959928 Paper 12225946 Paper 12149686 Paper 11460998 Paper 11404268 Paper 11290528 Paper 11254358 Paper 10906456 Paper 10891368 Paper 10801843 Paper 10781941 Paper 10704888

Abstract

DESCRIPTION (Adapted from applicant's abstract) The hypothesis is that keratinocyte growth factor (KGF) and laminin together with telomerase direct the fate of AEC between proliferation, differentiation, and/or apoptosis both during lung development and repair after lung injury through tyrosine phosphorylation cascades targeting cyclin D and retinoblastoma protein (pRb). Characterization of the molecular signaling mechanisms determining the proliferative versus apoptotic versus differentiated "survival" fate of AEC will identify new targets for the design of novel rational therapeutic approaches to amelioration of alveolar injury and augmentation of repair in both neonatal and adult human alveolar injury.

View original record on NIH RePORTER →